Product Description
Beraprost sodium (beraprost) is a stable, orally active prostacyclin analogue with vasodilatory, antiplatelet and cytoprotective effects. Beraprost acts by binding to prostacyclin membrane receptors ultimately inhibiting the release of Ca2+ from intracellular storage sites. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/11790158/)
Mechanisms of Action: PGI2 Angalogue
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Indonesia | Japan | Korea | Philippines | Thailand
Approved Indications: None
Known Adverse Events: None
Company: Sino Biopharmaceutical
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Chronic Pain|Intermittent Claudication
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CTR20230133 | P2 |
Completed |
Chronic Pain|Intermittent Claudication |
2023-04-11 |